Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

Non-Alcoholic Fatty Liver Disease Clinical Trial

— LFQ  

Official title:

Pilot Study of On-Cart Liver Fat Quantification (LFQ) Feature to Assess Correlation With Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) Results

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04657523
• Other study ID #: US-GIS-10481
• Status: Completed
• Phase: N/A
• Start date: October 30, 2020
• Est. completion date: January 18, 2023

Study information

• Verified date: January 2023
• Source: Philips Clinical & Medical Affairs Global
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). The primary objective of this clinical study is to evaluate the clinical feasibility of an investigational ultrasound technique for quantifying liver fat by comparing specific ultrasound-derived biomarkers with the liver fat percentage obtained from MRI Proton Density Fat Fraction (MRI-PDFF) measurements. All subjects enrolled in this study will undergo two investigational abdominal ultrasound examinations using the Philips EPIQ Ultrasound System and one MRI PDFF examination according to the clinical standard of care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: January 18, 2023
• Est. primary completion date: January 18, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be at least 18 years old and able to provide written informed consent

• Must attest to absent or minimal alcohol consumption (i.e. < 2 alcoholic beverages per day for women and < 3 alcoholic beverages per day for men, where an alcoholic beverage is defined as 12 oz. of regular beer, 5 oz. of wine, or 1.5 oz. of distilled spirits).

• Must be eligible for a standard abdominal ultrasound examination and standard non-contrast MRI examination.

• At least one of the following criteria must also be met: Overweight or obese (BMI = 25); Diagnosed with Type 2 diabetes; Diagnosed with hypercholesterolemia; Diagnosed with or clinically suspected of having NAFLD/NASH

Exclusion Criteria:

• Evidence of moderate/heavy/binge alcohol consumption exceeding the thresholds above

• Evidence of hepatotoxicity

• History of chronic liver disease (e.g., viral, cholestatic, or autoimmune).

• Use of drugs associated with hepatic steatosis

• Subjects anticipated or planned to undergo any diagnostic or therapeutic intervention during enrollment period that, at discretion of the Investigator, may affect liver fat content

• Hepatic lesions that cannot be excluded from the imaging field during ultrasound LFQ data acquisition

• History of previous liver surgery or hepatic implants that, at the discretion of the Investigator, may adversely impact ultrasound or MRI image quality or the subject's eligibility to undergo ultrasound or MRI

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Non-Alcoholic Steatohepatitis

Intervention

Device:
• Investigational Liver Fat Quantification Software
All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.

Locations

Country	Name	City	State
United States	Radiology Consultants, Inc	Boardman	Ohio
United States	Boston Medical Center	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Philips Clinical & Medical Affairs Global

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of the liver fat percentage reported from MRI-PDFF with measurements of ultrasound biomarkers for liver fat.	Correlation of each ultrasound biomarker with the liver fat percentage reported from MRI-PDFF will be assessed independently to evaluate individual biomarker performance.	Intra-procedural (1 day)
Secondary	Inter-operator variability in measurements of ultrasound biomarkers for liver fat	Inter-operator variability will be assessed by comparing the ultrasound biomarkers measured from each subject by two different operators who have received standardized training.	Intra-procedural (1 day)
Secondary	Ultrasound biomarker measurement failure rate	The ultrasound biomarker measurement failure rate will be assessed by measuring the percentage of subjects in whom measurements cannot be made due to technical limitations.	Intra-procedural (1 day)